Historical Stock Chart
1 Year : From Jul 2017 to Jul 2018
GHENT, Belgium, 15 November 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from C.H. Boehringer Sohn AG & Co KG on 13 November 2017.
C.H. Boehringer Sohn AG & Co KG notified Ablynx that it has been passively downward crossing the lowest threshold on 27 October 2017.
The notification contains the following information:
- Reason for the notification: downward crossing of the lowest threshold; passive crossing of a threshold
- Notification by: a parent undertaking or a controlling person
- Persons subject to the notification requirement: C.H. Boehringer Sohn AG & Co KG, BIR&D Beteiligungs GmbH
- Date on which threshold is crossed: 27 October 2017
- Threshold that is crossed: 3%
- Denominator: 73,006,144 (on 27 October 2017)
- Details of the notification: - (no details required when downward crossing the lowest threshold)
- Chain of controlled undertakings through which the holding is effectively being held: C.H. Boehringer Sohn AG & Co KG controls BIR&D Beteiligungs GmbH. C.H. Boehringer Sohn AG & Co KG is not controlled
- Additional information: Boehringer Ingelheim International GmbH has been replaced by BIR&D Beteiligungs GmbH as a result of a group internal reallocation
More information is provided in the transparency notification. Full versions of the transparency notifications are available on Ablynx website, under the section Investors.
The Articles of the Association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contactAblynx:Dr Edwin MosesCEOt: +32 (0)9 262 00 07m: +32 (0)473 39 50 68e: email@example.com
Lies VannesteDirector Investor Relationst: +32 (0)9 262 01 37m: +32 (0)498 05 35 79 e: firstname.lastname@example.org
Follow us on Twitter @AblynxABLX
Ablynx media relations:Consilium Strategic CommunicationsMary-Jane Elliott, Philippa Gardner, Sukaina Virjit: +44 (0)20 3709 5700e: email@example.com
DisclaimerCertain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.